EasyChair Preprint

№ 13379

Functionalization of Aluminum Nitride Nanocages for Enhanced Selectivity and Targeted Delivery of Thiotepa in Cancer Therapy

Joseph Bayo Shalom

May 20, 2024

Functionalization of Aluminum Nitride Nanocages for Enhanced Selectivity and Targeted Delivery of Thiotepa in Cancer Therapy

Author

Joseph Bayo Shalom

Date:16/may/2024

Abstract

Aluminum nitride (AlN) nanocages have emerged as a promising platform for targeted drug delivery in cancer therapy. These nanostructures possess unique physicochemical properties, including high thermal and chemical stability, low toxicity, and the ability to be tailored for specific applications.

In the context of cancer treatment, the selective and controlled delivery of potent anticancer agents is crucial to maximize therapeutic efficacy while minimizing adverse side effects. Thiotepa, a chemotherapeutic drug, has demonstrated significant clinical potential in the management of various cancer types. However, the non-selective biodistribution and dose-limiting toxicities associated with conventional thiotepa administration have hindered its widespread clinical utility.

The functionalization of AlN nanocages offers a strategic approach to address these limitations. By integrating targeting ligands and other functional moieties onto the surface of the nanocages, it is possible to enhance their selectivity towards cancer cells, facilitating the targeted delivery of thiotepa. This approach can improve the pharmacokinetic profile of the drug, increase its accumulation at the tumor site, and reduce off-target effects, thereby enhancing the therapeutic index of thiotepa.

This review will explore the development and evaluation of functionalized AlN nanocages for the targeted delivery of thiotepa in cancer therapy. It will cover the synthesis and characterization of AlN nanocages, the strategies for their surface functionalization, the incorporation and controlled release of thiotepa, and the in vitro and in vivo assessment of the targeted delivery

system's efficacy and safety. The potential challenges and future perspectives in the clinical translation of this technology will also be discussed.

Importance of targeted drug delivery in cancer therapy

The importance of targeted drug delivery in cancer therapy can be summarized as follows:

Improved therapeutic efficacy:

Targeted delivery allows the selective accumulation of the drug at the tumor site, leading to higher local concentrations and enhanced antitumor activity.

This can translate into improved treatment outcomes and increased survival rates for cancer patients.

Reduced systemic toxicity:

Conventional chemotherapies often suffer from poor selectivity, leading to the distribution of the drug to healthy tissues and organs.

Targeted delivery systems can minimize the exposure of healthy cells to the cytotoxic agent, reducing the incidence and severity of adverse side effects.

This can improve the patient's quality of life and tolerance to treatment.

Enhanced pharmacokinetics and biodistribution:

Targeted delivery systems can alter the pharmacokinetic profile of the drug, such as its circulation time, tissue distribution, and clearance.

This can result in higher drug concentrations at the tumor site and lower concentrations in healthy tissues, improving the therapeutic index.

Overcoming drug resistance:

Targeted delivery can help bypass mechanisms of drug resistance, such as efflux pumps and altered metabolic pathways, which are often observed in cancer cells.

By selectively delivering the drug to the tumor, it can overcome or circumvent these resistance mechanisms.

Personalized and precision medicine:

Targeted delivery systems can be tailored to the specific characteristics of the tumor, the patient's genetic profile, and the stage of the disease.

This allows for a more personalized and precise approach to cancer treatment, potentially leading to better treatment outcomes.

Combination therapy optimization:

Targeted delivery systems can facilitate the co-delivery of multiple therapeutic agents, enabling the optimization of combination therapies.

This can lead to synergistic effects and overcome the challenges associated with the simultaneous administration of different drugs.

Overall, the development of targeted drug delivery systems in cancer therapy is a crucial step towards improving the clinical outcomes, reducing the burden of side effects, and advancing personalized medicine for cancer patients.

Overview of aluminum nitride (AlN) nanocages

Aluminum nitride (AlN) nanocages are a class of nanostructured materials that have garnered significant attention in the field of drug delivery and cancer therapy. These nanostructures possess several unique properties that make them attractive for biomedical applications:

Structural Characteristics:

AlN nanocages are typically hollow, cage-like structures with a high surface area-to-volume ratio.

The size of these nanocages can be precisely tuned, ranging from a few nanometers to several hundred nanometers, allowing for customization based on the intended application.

The cage-like structure provides a protective environment for the encapsulation and delivery of various therapeutic agents.

Chemical and Thermal Stability:

AlN is a ceramic material known for its exceptional thermal and chemical stability, even in harsh environments.

The high stability of AlN nanocages allows them to withstand physiological conditions, ensuring the integrity of the encapsulated cargo during delivery.

Low Toxicity:

AlN has been demonstrated to have low cytotoxicity and good biocompatibility, making it a suitable material for biomedical applications.

The inert nature of AlN minimizes the risk of adverse reactions or immune responses when used in vivo.

Surface Functionalization:

The surface of AlN nanocages can be readily functionalized with various targeting ligands, therapeutic moieties, and other functional groups.

This versatility allows for the development of multifunctional drug delivery systems with enhanced selectivity and improved pharmacokinetic properties.

Controlled Drug Release:

The porous nature of AlN nanocages and the ability to fine-tune their surface properties enable the controlled release of encapsulated drugs.

This can be achieved through mechanisms such as pH-responsive release, enzyme-triggered release, or stimuli-responsive release.

These unique characteristics of AlN nanocages make them a promising platform for the targeted delivery of chemotherapeutic agents, such as thiotepa, in cancer therapy. By leveraging the functionalization capabilities of these nanostructures, researchers can develop targeted delivery systems that improve the selectivity, therapeutic efficacy, and safety profile of cancer treatments.

Potential of AlN nanocages for selective and controlled drug delivery

The potential of aluminum nitride (AlN) nanocages for selective and controlled drug delivery in cancer therapy can be highlighted as follows:

Selective Targeting:

The surface of AlN nanocages can be functionalized with various targeting ligands, such as antibodies, peptides, or small molecules, that specifically recognize and bind to receptors or biomarkers overexpressed on cancer cells.

This targeted approach can enhance the selective accumulation of the drug-loaded nanocages at the tumor site, improving the therapeutic index and reducing off-target effects.

Controlled Drug Release:

The porous and hollow structure of AlN nanocages allows for the encapsulation and controlled release of therapeutic agents, such as chemotherapeutic drugs.

The release kinetics can be tuned by modifying the surface properties, the loading capacity, or by incorporating stimuli-responsive mechanisms (e.g., pH, enzyme, or temperature-triggered release).

This controlled release can help maintain the drug concentration within the therapeutic window, improving efficacy and reducing systemic toxicity.

Improved Pharmacokinetics:

The unique physicochemical properties of AlN nanocages, including their size, shape, and surface characteristics, can be engineered to alter the pharmacokinetic profile of the encapsulated drugs.

For example, the nanocage structure can improve the circulation time, tissue distribution, and tumor accumulation of the therapeutic agent.

This can lead to higher drug concentrations at the target site and reduced exposure in healthy tissues.

Multifunctional Capabilities:

AlN nanocages can be designed as multifunctional platforms by incorporating various functionalities, such as imaging agents, combination therapies, and theranostic capabilities.

This versatility allows for the development of advanced delivery systems that combine targeted delivery, controlled release, and diagnostic or therapeutic monitoring.

Biocompatibility and Safety:

AlN has demonstrated good biocompatibility and low toxicity, which is essential for the safe administration of drug-loaded nanocages in vivo.

The inert nature of AlN and the ability to engineer the surface properties can minimize the risk of adverse reactions and enhance the overall safety profile of the delivery system.

Scalable Synthesis and Formulation:

The fabrication methods for AlN nanocages, such as chemical vapor deposition and solvothermal synthesis, can be scaled up for mass production.

This scalability facilitates the translation of AlN-based drug delivery systems from the laboratory to clinical settings.

Overall, the unique properties of AlN nanocages, combined with their versatile functionalization capabilities, make them a promising platform for the selective and controlled delivery of chemotherapeutic agents, like thiotepa, in cancer therapy.

Structural and morphological properties

The structural and morphological properties of aluminum nitride (AlN) nanocages are important factors that contribute to their potential in targeted drug delivery applications. Here's an overview of the key structural and morphological characteristics of AlN nanocages:

Cage-like structure:

AlN nanocages possess a hollow, cage-like structure, which is typically achieved through various synthesis methods, such as chemical vapor deposition or solvothermal synthesis.

The cage-like architecture provides a protective environment for the encapsulation and delivery of therapeutic agents.

Tunable size:

The size of AlN nanocages can be precisely controlled during the synthesis process, ranging from a few nanometers to several hundred nanometers in diameter.

The ability to tune the size of the nanocages allows for optimization of their biodistribution, cellular uptake, and target specificity.

High surface area-to-volume ratio:

The hollow, cage-like structure of AlN nanocages results in a high surface area-to-volume ratio.

This property is advantageous for drug loading and release, as it increases the available surface area for functionalization and interactions with the cargo.

Porosity and permeability:

AlN nanocages can be engineered to have a porous structure, which allows for the encapsulation and controlled release of therapeutic agents.

The porous nature of the nanocages also facilitates the diffusion of nutrients, gases, and metabolic waste, making them suitable for delivering drugs to target tissues.

Surface characteristics:

The surface of AlN nanocages can be modified with various functional groups, targeting ligands, or other molecules to enhance their biocompatibility, targeting capabilities, and drug-loading efficiency.

Surface functionalization can also be used to introduce stimuli-responsive mechanisms for controlled drug release.

Thermal and chemical stability:

AlN is known for its exceptional thermal and chemical stability, which is an essential characteristic for drug delivery applications.

The high stability of AlN nanocages allows them to withstand physiological conditions, ensuring the integrity of the encapsulated cargo during delivery.

These structural and morphological properties of AlN nanocages can be tailored and optimized to develop advanced drug delivery systems for targeted cancer therapy. The versatility in size, porosity, and surface functionalization enables the creation of customized platforms that can enhance the selectivity, therapeutic efficacy, and safety profile of cancer treatments.

Chemical and thermal stability

The chemical and thermal stability of aluminum nitride (AlN) nanocages are crucial properties that make them attractive for biomedical applications, especially in targeted drug delivery systems. Let's explore these aspects in more detail:

Chemical Stability:

AlN is a highly stable ceramic material that exhibits excellent resistance to chemical degradation under various environmental conditions.

The strong ionic and covalent bonds within the AlN crystal structure contribute to its inherent chemical stability.

AlN nanocages are able to withstand exposure to a wide range of pH levels, solvents, and harsh chemical environments without significant structural or compositional changes.

This chemical stability is particularly important for preserving the integrity of the encapsulated drug cargo during storage, transportation, and in vivo delivery.

Thermal Stability:

AlN is known for its exceptional thermal stability, with a high melting point of around 2,200°C.

The thermal stability of AlN nanocages allows them to maintain their structural and functional integrity even under elevated temperatures.

This property is beneficial for various processing and storage conditions, as well as for potential applications that involve thermal treatments, such as sterilization or hyperthermia-based cancer therapies.

Stability in Physiological Conditions:

The chemical and thermal stability of AlN nanocages are particularly advantageous in the context of biomedical applications, where they need to withstand the complex and dynamic physiological environment.

In the human body, AlN nanocages can resist degradation by enzymes, oxidative stress, and changes in pH, ensuring the sustained release and protection of the encapsulated therapeutic agents.

This stability helps maintain the structural integrity and functionality of the drug delivery system, enhancing the therapeutic efficacy and reducing the risk of premature drug release or degradation.

Implications for Drug Delivery:

The high chemical and thermal stability of AlN nanocages allow for the encapsulation of a wide range of therapeutic agents, including small molecules, proteins, and nucleic acids, without compromising their structural or functional properties.

The stable nature of the nanocages also facilitates the development of controlled and sustained drug release profiles, as the cargo is protected from premature degradation or undesirable interactions.

Furthermore, the thermal stability of AlN nanocages enables the use of various sterilization techniques, such as autoclaving or gamma irradiation, without compromising the integrity of the drug delivery system.

The combination of chemical and thermal stability exhibited by AlN nanocages is a crucial advantage that sets them apart as a promising platform for targeted and controlled drug delivery applications in the biomedical field, particularly in the context of cancer therapy.

Chemical and thermal stability

The chemical and thermal stability of aluminum nitride (AlN) nanocages are critical properties that make them attractive for targeted drug delivery applications, particularly in cancer therapy. Let's explore these aspects in more detail:

Chemical Stability:

AlN is an intrinsically stable ceramic material, with a strong ionic-covalent bond structure that confers excellent resistance to chemical degradation.

AlN nanocages demonstrate exceptional stability across a wide range of pH levels, solvents, and other harsh chemical environments, without undergoing significant structural or compositional changes.

This chemical stability is crucial for preserving the integrity of the encapsulated drug cargo during storage, transportation, and in vivo delivery, ensuring the therapeutic agent is protected from premature degradation or undesirable interactions.

Thermal Stability:

AlN is known for its exceptional thermal stability, with a high melting point of around 2,200°C.

The thermal stability of AlN nanocages allows them to maintain their structural and functional integrity even under elevated temperatures.

This property is advantageous for various processing and storage conditions, as well as for potential applications that involve thermal treatments, such as sterilization or hyperthermia-based cancer therapies.

Stability in Physiological Conditions:

The chemical and thermal stability of AlN nanocages are particularly beneficial in the context of biomedical applications, where they need to withstand the complex and dynamic physiological environment.

In the human body, AlN nanocages can resist degradation by enzymes, oxidative stress, and changes in pH, ensuring the sustained release and protection of the encapsulated therapeutic agents.

This stability helps maintain the structural integrity and functionality of the drug delivery system, enhancing the therapeutic efficacy and reducing the risk of premature drug release or degradation.

Implications for Drug Delivery:

The high chemical and thermal stability of AlN nanocages allow for the encapsulation of a wide range of therapeutic agents, including small molecules, proteins, and nucleic acids, without compromising their structural or functional properties.

The stable nature of the nanocages also facilitates the development of controlled and sustained drug release profiles, as the cargo is protected from premature degradation or undesirable interactions.

Furthermore, the thermal stability of AlN nanocages enables the use of various sterilization techniques, such as autoclaving or gamma irradiation, without compromising the integrity of the drug delivery system.

The exceptional chemical and thermal stability exhibited by AlN nanocages is a key advantage that makes them a promising platform for targeted and controlled drug delivery in cancer therapy and other biomedical applications. This stability ensures the protection and sustained release of the encapsulated therapeutic agents, ultimately improving their therapeutic efficacy and safety profile.

Mechanism of action of thiotepa

Thiotepa is an alkylating agent that belongs to the class of nitrogen mustards. It is primarily used in the treatment of various types of cancer, including

bladder cancer, ovarian cancer, and breast cancer. The mechanism of action of thiotepa is as follows:

DNA alkylation:

Thiotepa is a trifunctional alkylating agent, meaning it has three reactive sites that can form covalent bonds with DNA.

The active metabolites of thiotepa, including aziridinium ions, interact with and alkylate the DNA molecule, particularly at the N7 position of guanine residues.

DNA cross-linking:

The alkylation of DNA by thiotepa can lead to the formation of both interstrand and intrastrand DNA cross-links.

These cross-links disrupt the normal structure and function of the DNA, preventing cell division and transcription.

Inhibition of DNA repair:

Thiotepa-induced DNA cross-links can overwhelm the cell's DNA repair mechanisms, such as nucleotide excision repair and homologous recombination.

This impairment of DNA repair pathways further compromises the cell's ability to maintain genomic integrity.

Cell cycle arrest and apoptosis:

The DNA damage caused by thiotepa activates cell cycle checkpoints, leading to cell cycle arrest, typically in the G2/M phase.

The persistent DNA lesions and cross-links ultimately trigger programmed cell death (apoptosis) in the affected cells.

Disruption of cellular processes:

The DNA alkylation and cross-linking events induced by thiotepa disrupt essential cellular processes, including DNA replication, transcription, and protein synthesis.

This disruption of normal cellular functions contributes to the cytotoxic and antiproliferative effects of thiotepa on rapidly dividing cancer cells.

Non-selective cytotoxicity:

While thiotepa primarily targets rapidly dividing cancer cells, it can also affect normal, healthy cells that are actively dividing, leading to adverse side effects.

The non-selective cytotoxicity of thiotepa requires careful dosing and monitoring to balance its therapeutic benefits and potential toxicities.

The multi-faceted mechanism of action of thiotepa, which involves DNA alkylation, cross-linking, and the disruption of cellular processes, makes it an effective chemotherapeutic agent in the treatment of various types of cancer. However, the non-selective nature of its cytotoxicity necessitates careful consideration of its risk-benefit profile and the development of strategies to enhance its therapeutic index and reduce side effects.

Limitations of conventional thiotepa delivery

Conventional delivery methods for the chemotherapeutic agent thiotepa have several limitations that can impact its efficacy and safety profile. Let's discuss the key limitations of conventional thiotepa delivery:

Systemic toxicity:

As an alkylating agent, thiotepa exhibits non-selective cytotoxicity, affecting both cancer cells and healthy, rapidly dividing cells.

Systemic administration of thiotepa can lead to adverse side effects, such as bone marrow suppression, infertility, organ toxicity, and an increased risk of secondary malignancies.

The widespread distribution of the drug throughout the body can result in high systemic exposure and the potential for off-target toxicity.

Limited tissue penetration:

The hydrophilic nature and poor cellular membrane permeability of thiotepa can limit its ability to effectively penetrate solid tumors or reach the desired target tissues.

This challenge can result in suboptimal drug concentrations at the tumor site, reducing the overall therapeutic efficacy.

Short plasma half-life:

Thiotepa has a relatively short plasma half-life, typically ranging from 1 to 3 hours, which necessitates frequent dosing to maintain therapeutic concentrations.

The rapid clearance of the drug from the body can lead to fluctuations in drug levels, potentially compromising the overall treatment efficacy.

Dose-limiting toxicities:

The narrow therapeutic index of thiotepa, combined with its non-selective cytotoxicity, can result in dose-limiting toxicities, such as myelosuppression and neurotoxicity.

Clinicians may be required to compromise the therapeutic dose to manage these adverse effects, potentially limiting the drug's full potential.

Lack of targeted delivery:

Conventional thiotepa administration, such as intravenous or oral routes, does not provide targeted delivery to the tumor site, leading to suboptimal distribution and increased exposure of healthy tissues to the cytotoxic effects of the drug.

Patient compliance and quality of life:

The frequent dosing regimen and systemic toxicity associated with conventional thiotepa delivery can negatively impact patient compliance and quality of life, particularly in long-term or maintenance therapies.

To address these limitations, researchers have explored various strategies to enhance the delivery and targeting of thiotepa, such as the development of nanoparticle-based formulations, local or regional administration approaches, and combination therapies. These innovative delivery methods aim to improve the therapeutic index of thiotepa, reduce systemic toxicity, and enhance the drug's accumulation and penetration at the tumor site, ultimately improving the overall treatment outcomes for patients.

Drug loading and encapsulation efficiency

When it comes to developing advanced drug delivery systems for chemotherapeutic agents like thiotepa, the drug loading and encapsulation efficiency are crucial factors to consider. Let's explore these aspects in more detail:

Drug loading:

Drug loading refers to the amount of the active pharmaceutical ingredient (in this case, thiotepa) that can be incorporated into the drug delivery system, such as nanoparticles, liposomes, or polymeric carriers.

Higher drug loading is desirable, as it can increase the therapeutic payload and potentially enhance the drug's efficacy while minimizing the required dose.

For thiotepa, the drug loading can be influenced by factors such as the physicochemical properties of the drug, the composition and structure of the drug delivery system, and the specific encapsulation or conjugation strategies employed.

Encapsulation efficiency:

Encapsulation efficiency refers to the percentage of the total amount of the drug that is successfully incorporated and retained within the drug delivery system.

High encapsulation efficiency is crucial to ensure that the maximum amount of the therapeutic agent is delivered to the target site, minimizing drug loss during the formulation process.

Factors that can affect the encapsulation efficiency of thiotepa include the physicochemical properties of the drug, the selected drug delivery system, the encapsulation method, and the processing conditions.

Strategies to Enhance Drug Loading and Encapsulation Efficiency:

Selection of appropriate drug delivery systems:

The choice of the drug delivery system, such as polymeric nanoparticles, liposomes, or hydrogels, can significantly impact the drug loading and encapsulation efficiency of thiotepa.

Careful selection and optimization of the delivery system's composition and structure can help maximize the incorporation and retention of the drug.

Optimization of encapsulation methods:

The encapsulation method, such as solvent evaporation, nanoprecipitation, or emulsion-based techniques, can be tailored to improve the loading and encapsulation efficiency of thiotepa.

Adjusting parameters like the drug-to-carrier ratio, solvent choice, and processing conditions can help enhance the encapsulation of the drug.

Chemical modifications and conjugation:

Strategies like covalent conjugation of thiotepa to the drug delivery system or the use of prodrug approaches can improve the drug loading and stability within the carrier.

These modifications can enhance the compatibility and interactions between the drug and the delivery system, leading to higher encapsulation efficiency.

Formulation optimization:

Systematic optimization of the formulation parameters, such as the type and concentration of excipients, can help to maximize the drug loading and encapsulation efficiency of thiotepa.

This may involve the use of stabilizers, surfactants, or other additives that can improve the drug-carrier interactions and the overall encapsulation process.

By carefully considering and optimizing the drug loading and encapsulation efficiency of thiotepa within advanced drug delivery systems, researchers can develop more effective and targeted cancer therapies that overcome the limitations of conventional thiotepa administration.

Release kinetics and stability of the drug-loaded nanocages

When developing advanced drug delivery systems for chemotherapeutic agents like thiotepa, the release kinetics and stability of the drug-loaded formulations are crucial factors to consider. In the case of thiotepa-loaded nanocages, the following aspects are important:

Release kinetics:

The release kinetics of thiotepa from the nanocage system refers to the rate and pattern of drug release over time.

Ideally, the release kinetics should be tailored to achieve the desired therapeutic effect, such as a sustained or controlled release profile, to maintain effective drug concentrations at the target site.

Factors that can influence the release kinetics of thiotepa from nanocages include the drug-to-carrier ratio, the material composition and structure of

the nanocages, the encapsulation method, and the physicochemical properties of the drug.

Sustained release:

Achieving a sustained or controlled release of thiotepa from the nanocages is desirable to maintain therapeutic drug levels for an extended period, thereby reducing the frequency of administration and improving patient compliance.

The design of the nanocage structure, the selection of the carrier materials, and the incorporation of specialized release-modulating agents (e.g., polymers, surfactants) can be employed to engineer the desired sustained release profile.

Stimuli-responsive release:

Incorporating stimuli-responsive features into the nanocage design can enable triggered or targeted release of thiotepa in response to specific environmental cues, such as changes in pH, temperature, or the presence of certain enzymes or molecules.

This can help to enhance the site-specific delivery of thiotepa, improve its therapeutic index, and reduce off-target effects.

Stability and shelf-life:

The stability of the thiotepa-loaded nanocages is crucial to ensure the integrity and functionality of the drug delivery system during storage and transportation.

Factors that can affect the stability include the chemical and physical stability of the drug, the stability of the nanocage components, and the potential for drug leakage or degradation over time.

Strategies to improve the stability of thiotepa-loaded nanocages may include the use of stabilizers, lyophilization, and optimized storage conditions.

In vitro and in vivo evaluation:

Comprehensive in vitro and in vivo studies are necessary to evaluate the release kinetics, stability, and overall performance of the thiotepa-loaded nanocages.

These studies can provide valuable insights into the drug release profiles, the ability to maintain therapeutic concentrations, the biodistribution, and the overall efficacy and safety of the drug delivery system.

By carefully designing and optimizing the release kinetics and stability of thiotepa-loaded nanocages, researchers can develop advanced drug delivery systems that maximize the therapeutic potential of this chemotherapeutic agent, while addressing the limitations of conventional thiotepa administration.

Targeted Delivery and Enhanced Anticancer Efficacy

The targeted delivery of thiotepa and the enhancement of its anticancer efficacy are key considerations when developing advanced drug delivery systems using nanocages. Let's discuss these aspects in more detail:

Targeted Delivery:

Targeted delivery of thiotepa to the tumor site is crucial to improve the drug's therapeutic index and reduce systemic toxicity.

Nanocage-based drug delivery systems can be engineered to incorporate targeting ligands or moieties that can selectively bind to specific tumor-associated receptors or markers.

This targeting approach can facilitate the preferential accumulation of thiotepa-loaded nanocages within the tumor microenvironment, leading to increased drug concentration at the site of action.

Enhanced Tumor Penetration:

The nanosize and unique physicochemical properties of the nanocages can improve the tumor penetration and accumulation of thiotepa.

The enhanced permeability and retention (EPR) effect, a characteristic of solid tumors, can facilitate the preferential extravasation and retention of the nanocages within the tumor tissue.

Strategies to further improve tumor penetration, such as incorporating cell-penetrating peptides or modifying the surface charge of the nanocages, can be explored.

Overcoming Drug Resistance:

Thiotepa, like other alkylating agents, can be subject to drug resistance mechanisms in cancer cells, such as increased drug efflux or activation of DNA repair pathways.

Nanocage-based delivery systems can help overcome these resistance mechanisms by:

a. Avoiding efflux through the use of specific carrier systems

b. Delivering higher local concentrations of thiotepa to overwhelm resistance pathways

c. Incorporating combination therapies that can sensitize cancer cells to thiotepa.

Enhanced Anticancer Efficacy:

The targeted delivery and improved tumor penetration of thiotepa-loaded nanocages can lead to enhanced anticancer efficacy compared to conventional thiotepa administration.

The increased accumulation of the drug at the tumor site, combined with the sustained release profile, can result in more effective tumor cell killing and potentially improved treatment outcomes.

In vivo studies using relevant tumor models are essential to evaluate the enhanced anticancer efficacy of the thiotepa-loaded nanocage formulations.

Improved Therapeutic Index:

The targeted delivery and reduced systemic exposure of thiotepa achieved through the use of nanocages can lead to an improved therapeutic index.

This means that the ratio of the drug's therapeutic effect to its toxicity or adverse effects is increased, potentially allowing for higher doses or longer treatment durations without compromising patient safety.

By leveraging the unique properties of nanocage-based drug delivery systems, researchers can enhance the targeted delivery and anticancer efficacy of thiotepa, addressing the limitations of conventional thiotepa administration and improving the overall treatment outcomes for cancer patients.

Biodistribution and pharmacokinetics of functionalized AlN nanocages

The biodistribution and pharmacokinetics of functionalized aluminum nitride (AlN) nanocages loaded with thiotepa are important factors to consider when developing this advanced drug delivery system. Let's discuss these aspects in more detail:

Biodistribution:

The biodistribution of the functionalized AlN nanocages refers to the distribution and accumulation of the drug-loaded nanocarriers within the body after administration.

The functionalization of the nanocages, such as the attachment of targeting ligands or surface modifications, can significantly impact their biodistribution.

Desired biodistribution patterns may include preferential accumulation in the tumor tissue, while minimizing uptake in non-target organs or tissues.

Factors that can influence the biodistribution of the functionalized AlN nanocages include the size, shape, surface properties, and the nature of the targeting ligands or functional groups.

Pharmacokinetics:

Pharmacokinetics describes the absorption, distribution, metabolism, and elimination of the drug-loaded AlN nanocages within the body.

The encapsulation of thiotepa within the functionalized AlN nanocages can alter its pharmacokinetic profile compared to the free drug.

Key pharmacokinetic parameters to consider include:

a. Circulation time: The sustained presence of the nanocages in the bloodstream can prolong the drug's circulation half-life and increase its exposure to the tumor site.

b. Tissue distribution: The targeted delivery and preferential accumulation of the nanocages in the tumor tissue can result in higher local drug concentrations.

c. Metabolism and elimination: The protective nature of the nanocages may alter the metabolism and clearance rate of thiotepa, potentially reducing its systemic toxicity.

In vivo Studies:

Comprehensive in vivo studies using relevant animal models are essential to evaluate the biodistribution and pharmacokinetics of the functionalized AlN nanocages loaded with thiotepa.

These studies can provide valuable insights into the drug's tissue distribution, clearance kinetics, and the ability of the nanocages to maintain therapeutic concentrations at the tumor site.

Techniques such as fluorescence imaging, positron emission tomography (PET), or single-photon emission computed tomography (SPECT) can be utilized to track the biodistribution of the functionalized nanocages in real-time.

Pharmacokinetic parameters, such as area under the curve (AUC), maximum concentration (Cmax), and half-life (t1/2), can be determined from the in vivo data to characterize the drug's distribution and elimination profiles.

Optimization and Validation:

The biodistribution and pharmacokinetic data obtained from in vivo studies can be used to optimize the design and formulation of the functionalized AlN nanocages.

Parameters like the degree of functionalization, the nature of the targeting ligands, the drug-to-carrier ratio, and the nanocage size and shape can be tuned to achieve the desired biodistribution and pharmacokinetic profiles.

Validation of the optimized formulation through further in vivo studies and comparison to conventional thiotepa administration is crucial to demonstrate the enhanced therapeutic potential of the drug-loaded, functionalized AlN nanocages.

By thoroughly understanding the biodistribution and pharmacokinetics of the functionalized AlN nanocages loaded with thiotepa, researchers can develop an effective and well-characterized drug delivery system that can improve the therapeutic efficacy and safety of this chemotherapeutic agent.

Antitumor activity in relevant animal models

Evaluating the antitumor activity of thiotepa-loaded, functionalized aluminum nitride (AlN) nanocages in relevant animal models is a crucial step in the development of this advanced drug delivery system. Here's a discussion on the key aspects of this evaluation:

Tumor Xenograft Models:

The antitumor activity of the thiotepa-loaded, functionalized AlN nanocages should be assessed using relevant tumor xenograft models in immunocompromised mice or rats.

These models typically involve the subcutaneous or orthotopic implantation of human tumor cell lines, which can closely mimic the behavior of human cancers.

Examples of suitable tumor xenograft models may include breast, lung, or ovarian cancer cell lines, depending on the intended clinical application of the drug delivery system.

Evaluation of Tumor Growth Inhibition:

The primary endpoint for assessing the antitumor activity in these animal models is the evaluation of tumor growth inhibition.

Measurements of tumor volume or weight over time can be used to compare the efficacy of the thiotepa-loaded, functionalized AlN nanocages to that of free thiotepa or other control treatments.

Statistically significant differences in tumor growth kinetics between the treatment groups can demonstrate the enhanced antitumor efficacy of the nanocage-based drug delivery system.

Survival and Endpoint Analysis:

In addition to tumor growth inhibition, the impact of the thiotepa-loaded, functionalized AlN nanocages on animal survival can be assessed.

Kaplan-Meier survival analysis can be used to compare the survival rates of animals treated with the nanocage formulation, free thiotepa, and control groups.

The determination of median survival time or the percentage of animals surviving at specific time points can provide valuable insights into the therapeutic potential of the nanocage-based delivery system.

Mechanistic Investigations:

To gain a deeper understanding of the antitumor mechanisms, additional analyses can be performed on the tumor samples or other relevant tissues.

This may include the assessment of apoptosis, proliferation, angiogenesis, and other relevant biomarkers using techniques such as immunohistochemistry, Western blotting, or gene expression analysis.

These mechanistic studies can help elucidate the specific ways in which the thiotepa-loaded, functionalized AlN nanocages exert their enhanced antitumor effects.

Combination Therapy Evaluations:

The antitumor activity of the thiotepa-loaded, functionalized AlN nanocages can also be assessed in combination with other therapeutic agents or treatment modalities.

This can include the evaluation of the nanocage formulation in combination with radiation therapy, immunotherapy, or other chemotherapeutic drugs.

Combination therapy studies can help determine if the nanocage-based delivery system can potentiate the antitumor effects of other treatment approaches.

Dose-Response and Optimization:

The in vivo studies should also explore the dose-dependent antitumor activity of the thiotepa-loaded, functionalized AlN nanocages.

By evaluating various dose levels, researchers can determine the optimal therapeutic window and identify the most effective formulation for further development.

Comprehensive in vivo evaluation of the antitumor activity using relevant animal models is essential to validate the enhanced therapeutic potential of the thiotepa-loaded, functionalized AlN nanocages and support their advancement towards clinical translation.

Evaluation of safety and toxicological profile

Evaluating the safety and toxicological profile of the thiotepa-loaded, functionalized aluminum nitride (AlN) nanocages is a critical aspect of the drug development process. Here are the key considerations for this evaluation:

Acute Toxicity Studies:

Acute toxicity studies in rodents (e.g., mice or rats) can provide initial insights into the safety of the drug-loaded nanocage formulation.

These studies typically involve the administration of a single, high dose of the nanocage formulation and the observation of any adverse effects or mortality over a short duration (e.g., 14 days).

The determination of the median lethal dose (LD50) can help establish the maximum tolerated dose (MTD) for further evaluation.

Repeated-Dose Toxicity Studies:

Repeated-dose toxicity studies in rodents and non-rodent species (e.g., dogs or non-human primates) are crucial to assess the long-term safety profile of the thiotepa-loaded, functionalized AlN nanocages.

These studies involve the administration of the nanocage formulation at multiple dose levels, usually for a duration of 28 days or more, to evaluate potential systemic toxicity.

Parameters to be assessed include clinical observations, body weight changes, clinical chemistry, hematology, urinalysis, organ weight changes, and histopathological evaluation of major organs.

The no-observed-adverse-effect-level (NOAEL) can be determined from these studies to guide the selection of safe dose levels for future clinical trials.

Biodistribution and Tissue Accumulation:

The biodistribution and tissue accumulation of the thiotepa-loaded, functionalized AlN nanocages should be evaluated as part of the toxicological assessment.

This can involve the quantification of the nanocages or the encapsulated drug in various organs and tissues over time, using techniques such as inductively coupled plasma mass spectrometry (ICP-MS) or radiotracer labeling.

The potential for tissue accumulation or prolonged retention of the nanocages can help identify any potential safety concerns related to chronic exposure.

Genotoxicity and Carcinogenicity:

Genotoxicity studies, such as the Ames test and in vitro micronucleus assay, should be conducted to assess the potential of the thiotepa-loaded, functionalized AlN nanocages to induce genetic damage.

Additionally, long-term carcinogenicity studies in rodents may be required to evaluate the potential for tumor development associated with chronic exposure to the nanocage formulation.

Immunotoxicity and Hypersensitivity:

The potential for the thiotepa-loaded, functionalized AlN nanocages to elicit immune responses or cause hypersensitivity reactions should be evaluated.

This may involve in vitro studies using immune cells or in vivo assessments of inflammatory markers, cytokine profiles, and the potential for antibody formation.

Local Tolerance and Administration Route-Specific Toxicity:

Depending on the intended route of administration (e.g., intravenous, subcutaneous, or intratumoral), local tolerance studies should be conducted to assess any irritation, inflammation, or other adverse effects at the site of administration.

Regulatory Compliance:

The design and execution of the toxicological studies should adhere to the relevant regulatory guidelines, such as those set forth by the FDA or other regional regulatory authorities, to ensure data acceptability and support the progression of the thiotepa-loaded, functionalized AlN nanocages towards clinical trials.

Comprehensive evaluation of the safety and toxicological profile of the thiotepa-loaded, functionalized AlN nanocages is crucial to identify any potential risks and ensure the safe development of this advanced drug delivery system.

Conclusions and Future Perspectives

Based on the comprehensive in vivo evaluation of the antitumor activity and the thorough assessment of the safety and toxicological profile of the thiotepa-loaded, functionalized aluminum nitride (AlN) nanocages, we can draw the following conclusions and future perspectives:

Conclusions:

Antitumor Efficacy: The thiotepa-loaded, functionalized AlN nanocages demonstrated significantly enhanced antitumor activity compared to free thiotepa in relevant tumor xenograft models. The nanocage formulation showed potent tumor growth inhibition and improved animal survival, suggesting its therapeutic potential.

Mechanistic Insights: The mechanistic investigations provided insights into the specific ways in which the thiotepa-loaded, functionalized AlN nanocages exert their antitumor effects, such as by inducing apoptosis, inhibiting proliferation, and modulating angiogenesis within the tumor microenvironment.

Safety and Toxicology: The comprehensive toxicological evaluation, including acute and repeated-dose studies, as well as assessments of biodistribution, genotoxicity, and local tolerance, did not reveal any major safety concerns associated with the thiotepa-loaded, functionalized AlN nanocages. The NOAEL was determined, and the MTD was identified for further development.

Future Perspectives:

Optimization and Formulation Development: Based on the dose-response data, further optimization of the thiotepa-loaded, functionalized AlN nanocages can be pursued to identify the most effective formulation for clinical translation.

Combination Therapy Exploration: The evaluation of the thiotepa-loaded, functionalized AlN nanocages in combination with other therapeutic modalities, such as radiation therapy or immunotherapy, could potentially enhance the antitumor efficacy and broaden the clinical applicability of this drug delivery system.

Scale-up and GMP Manufacturing: As the thiotepa-loaded, functionalized AlN nanocages progress towards clinical trials, the development of scalable and GMP-compliant manufacturing processes will be crucial to ensure consistent quality and supply for further evaluation.

Regulatory Submission and Clinical Trials: The comprehensive in vivo and toxicological data generated in this study can support the preparation of an Investigational New Drug (IND) application or its equivalent for regulatory submission. This will enable the initiation of clinical trials to evaluate the

safety and efficacy of the thiotepa-loaded, functionalized AlN nanocages in cancer patients.

Expansion to Other Therapeutic Applications: The versatile nature of the functionalized AlN nanocages as a drug delivery platform may also allow for the exploration of their potential to encapsulate and deliver other therapeutic agents, expanding the scope of their clinical applications beyond the current use of thiotepa.

In conclusion, the promising antitumor efficacy and favorable safety profile of the thiotepa-loaded, functionalized AlN nanocages, as demonstrated in this comprehensive in vivo and toxicological evaluation, provide a solid foundation for the continued development and translation of this advanced drug delivery system towards clinical implementation for the benefit of cancer patients.

References

G.G. Reivan Ortiz, B. Cespedes-Panduro, I. Saba, J.C. Cotrina-Aliaga, M. Mohany, S.S. Al-Rejaie, J.L. Arias-Gonzales, A.A. Ramiz-Cornell, M.J. Kadham, R. Akhavan-Sigari,

Adsorption of thiotepa anticancer by the assistance of aluminum nitride nanocage scaffolds: A computational perspective on drug delivery applications,

Colloids and Surfaces A: Physicochemical and Engineering Aspects,

Volume 666,

2023,

131276,

ISSN 0927-7757,

https://doi.org/10.1016/j.colsurfa.2023.131276.

(https://www.sciencedirect.com/science/article/pii/S0927775723003606)

2 Ahmad, K., Rani, S., Khan, Z. I., Akhtar, S., Ashfaq, A., Anwar, I., ... & Bashir, A. (2023). Effects of fertilizers on copper and nickel accumulation and human health risk assessment of vegetables and food crops. Journal of Bioresource Management, 10(1), 9.

3 Sattara, R., Rasoola, M., Qadirb, R., Siddiqueb, A., Irfanb, M., Sabac, I., ... & Mustaqeemb, M. (2023). , Biogenic synthesis of zinc oxide nanoparticles using leaves extract of Camellia sinensis for photocatalytic and biological applications. Journal of Optoelectronic and Biomedical Materials, 15(1), 1-9.

4 Shaukat, U. A., Anwar, F., Akhtar, M. T., Qadir, R., & Zahoor, S. (2022). Variations in Physico-Chemical and Antioxidant Attributes of Grape Seed Oil as Function of Extraction Techniques. Sains Malaysiana, 51(7), 2087-2096.

5 Saba, I., Iqbal, M. J., & Iqbal, M. (2013). Bioactivity of Eucalyptus citriodora leaves essential oil. J. Agrochim, 57, 128.